FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1617588077> ?p ?o ?g. }

• W1617588077 endingPage "925" @default.
• W1617588077 startingPage "918" @default.
• W1617588077 abstract "The transthyretin (TTR) stabilizer, tafamidis, has demonstrated efficacy and safety in the treatment of TTR familial amyloid polyneuropathy (20 mg day(-1) ). Tafamidis use in TTR cardiomyopathy led to the study of the potential effect of tafamidis on the QTc interval in healthy subjects.This randomized, three treatment, three period, six sequence crossover study with placebo, a positive control (moxifloxacin 400 mg) and tafamidis (400 mg, to achieve a supra-therapeutic Cmax of ~20 µg ml(-1) ) was conducted in healthy volunteers at three clinical research units. Oral dosing in each of the three treatment periods was separated by a washout period of ≥ 14 days. Serial triplicate 12-lead electrocardiograms were performed. QTc intervals were derived using the Fridericia correction method. Safety and tolerability were assessed by physical examination, vital signs measurement, laboratory analyses and monitoring of adverse events (AEs).A total of 42 subjects completed the study. The upper limit of the two-sided 90% confidence intervals (CIs) for the difference in baseline-adjusted QTc F between tafamidis 400 mg and placebo was <10 ms (non-inferiority criterion) for all time points. The lower limit of the two-sided 90% CI between moxifloxacin 400 mg and placebo exceeded 5 ms at the pre-specified moxifloxacin tmax of 3 h post-dose, confirming assay sensitivity. Cmax and AUC(0,24 h) for tafamidis were 20.36 µg ml(-1) and 305.4 µg ml(-1) h, respectively. There were no serious/severe AEs or treatment discontinuations due to AEs.This thorough QTc study suggests that a supra-therapeutic single 400 mg oral dose of tafamidis does not prolong the QTc interval and is well-tolerated in healthy volunteers." @default.
• W1617588077 created "2016-06-24" @default.
• W1617588077 creator A5003649836 @default.
• W1617588077 creator A5005473186 @default.
• W1617588077 creator A5006980191 @default.
• W1617588077 creator A5031560013 @default.
• W1617588077 creator A5040879909 @default.
• W1617588077 date "2015-05-22" @default.
• W1617588077 modified "2023-09-23" @default.
• W1617588077 title "The effect of tafamidis on the QT_cinterval in healthy subjects" @default.
• W1617588077 cites W1568589356 @default.
• W1617588077 cites W1579462161 @default.
• W1617588077 cites W1968925833 @default.
• W1617588077 cites W1972373816 @default.
• W1617588077 cites W1985918137 @default.
• W1617588077 cites W1996927016 @default.
• W1617588077 cites W2011246655 @default.
• W1617588077 cites W2025112049 @default.
• W1617588077 cites W2043290117 @default.
• W1617588077 cites W2080914865 @default.
• W1617588077 cites W2094587801 @default.
• W1617588077 cites W2096319356 @default.
• W1617588077 cites W2115862827 @default.
• W1617588077 cites W2131999691 @default.
• W1617588077 cites W2132858917 @default.
• W1617588077 cites W2135565738 @default.
• W1617588077 doi "https://doi.org/10.1111/bcp.12561" @default.
• W1617588077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4456124" @default.
• W1617588077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25546001" @default.
• W1617588077 hasPublicationYear "2015" @default.
• W1617588077 type Work @default.
• W1617588077 sameAs 1617588077 @default.
• W1617588077 citedByCount "14" @default.
• W1617588077 countsByYear W16175880772015 @default.
• W1617588077 countsByYear W16175880772016 @default.
• W1617588077 countsByYear W16175880772019 @default.
• W1617588077 countsByYear W16175880772020 @default.
• W1617588077 countsByYear W16175880772021 @default.
• W1617588077 countsByYear W16175880772022 @default.
• W1617588077 crossrefType "journal-article" @default.
• W1617588077 hasAuthorship W1617588077A5003649836 @default.
• W1617588077 hasAuthorship W1617588077A5005473186 @default.
• W1617588077 hasAuthorship W1617588077A5006980191 @default.
• W1617588077 hasAuthorship W1617588077A5031560013 @default.
• W1617588077 hasAuthorship W1617588077A5040879909 @default.
• W1617588077 hasBestOaLocation W16175880771 @default.
• W1617588077 hasConcept C112705442 @default.
• W1617588077 hasConcept C118441451 @default.
• W1617588077 hasConcept C126322002 @default.
• W1617588077 hasConcept C142724271 @default.
• W1617588077 hasConcept C185592680 @default.
• W1617588077 hasConcept C197934379 @default.
• W1617588077 hasConcept C204787440 @default.
• W1617588077 hasConcept C22979827 @default.
• W1617588077 hasConcept C27081682 @default.
• W1617588077 hasConcept C2777288759 @default.
• W1617588077 hasConcept C2778375690 @default.
• W1617588077 hasConcept C2778836808 @default.
• W1617588077 hasConcept C42219234 @default.
• W1617588077 hasConcept C44249647 @default.
• W1617588077 hasConcept C501593827 @default.
• W1617588077 hasConcept C55493867 @default.
• W1617588077 hasConcept C71924100 @default.
• W1617588077 hasConcept C87813604 @default.
• W1617588077 hasConcept C98274493 @default.
• W1617588077 hasConceptScore W1617588077C112705442 @default.
• W1617588077 hasConceptScore W1617588077C118441451 @default.
• W1617588077 hasConceptScore W1617588077C126322002 @default.
• W1617588077 hasConceptScore W1617588077C142724271 @default.
• W1617588077 hasConceptScore W1617588077C185592680 @default.
• W1617588077 hasConceptScore W1617588077C197934379 @default.
• W1617588077 hasConceptScore W1617588077C204787440 @default.
• W1617588077 hasConceptScore W1617588077C22979827 @default.
• W1617588077 hasConceptScore W1617588077C27081682 @default.
• W1617588077 hasConceptScore W1617588077C2777288759 @default.
• W1617588077 hasConceptScore W1617588077C2778375690 @default.
• W1617588077 hasConceptScore W1617588077C2778836808 @default.
• W1617588077 hasConceptScore W1617588077C42219234 @default.
• W1617588077 hasConceptScore W1617588077C44249647 @default.
• W1617588077 hasConceptScore W1617588077C501593827 @default.
• W1617588077 hasConceptScore W1617588077C55493867 @default.
• W1617588077 hasConceptScore W1617588077C71924100 @default.
• W1617588077 hasConceptScore W1617588077C87813604 @default.
• W1617588077 hasConceptScore W1617588077C98274493 @default.
• W1617588077 hasIssue "6" @default.
• W1617588077 hasLocation W16175880771 @default.
• W1617588077 hasLocation W16175880772 @default.
• W1617588077 hasLocation W16175880773 @default.
• W1617588077 hasLocation W16175880774 @default.
• W1617588077 hasOpenAccess W1617588077 @default.
• W1617588077 hasPrimaryLocation W16175880771 @default.
• W1617588077 hasRelatedWork W1604467628 @default.
• W1617588077 hasRelatedWork W2056242922 @default.
• W1617588077 hasRelatedWork W2064759457 @default.
• W1617588077 hasRelatedWork W2074207917 @default.
• W1617588077 hasRelatedWork W2085287792 @default.
• W1617588077 hasRelatedWork W2094883508 @default.
• W1617588077 hasRelatedWork W2332733266 @default.

• next